Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation through Activating PPARα Pathway

BACKGROUNDS: We recently reported that Naoxintong (NXT), a China Food and Drug Administration (FDA)-approved cardiac medicine, could reduce the plaque size, but the underlying mechanism remains elusive now. OBJECTIVE: In this study, we investigated the effects of NXT on foam cell accumulation both i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Curr Mol Med
Autori principali: Wang, Zeng, Shi, Huairui, Zhao, Huan, Dong, Zhen, Zhao, Buchang, Weng, Xinyu, Liu, Rongle, Hu, Kai, Zou, Yunzeng, Sun, Aijun, Ge, Junbo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Bentham Science Publishers 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463403/
https://ncbi.nlm.nih.gov/pubmed/30734676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1566524019666190207143207
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi